Targeted therapies of the LKB1/AMPK pathway for the treatment of insulin resistance

Eijiro Yamada, Ting Wen A. Lee, Jeffrey E. Pessin, Claire C. Bastie

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations


Type II diabetes is characterized by elevated serum glucose levels and altered lipid metabolism due to peripheral insulin resistance and defects of insulin secretion in the pancreatic -cells. While some cases of obesity and Type II diabetes result from genetic dysfunction, the increased worldwide incidence of these two disorders strongly suggest that the contribution of environmental factors such as sedentary lifestyles and high-calorie intake may disrupt energy balance. AMP-activated protein kinase and its upstream kinase liver kinase B1 are conserved serine/threonine kinases regulating anabolic and catabolic metabolic processes, therefore representing attractive therapeutic targets for the treatment of obesity and Type II diabetes. In this review, we will discuss the advantages of targeting the liver kinase B1/AMP-activated protein kinase pathway for the treatment of metabolic diseases.

Original languageEnglish (US)
Pages (from-to)1785-1796
Number of pages12
JournalFuture Medicinal Chemistry
Issue number12
StatePublished - Dec 2010

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Targeted therapies of the LKB1/AMPK pathway for the treatment of insulin resistance'. Together they form a unique fingerprint.

Cite this